linjc16/ctgov huggingface dataset:
Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

Study Overview
=================
Brief Summary
-----------------
Deficits in memory, executive function, and language are common cognitive sequelae of aneurysmal subarachnoid hemorrhage (aSAH). Previous study demonstrated that post-treatment antiplatelet therapy reduced risk for delayed cerebral ischemia caused by aSAH. However, the effect of antiplatelet therapy on cognition after aSAH is unclear. The aim of this study was to assess the effect of antiplatelet therapy on cognition after aSAH.

Official Title
-----------------
Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

Conditions
-----------------
Aneurysmal Subarachnoid Hemorrhage

Intervention / Treatment
-----------------
* Drug: Antiplatelet Drug


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 1. Patients with SAH in whom the aneurysm was proven by conventional angiography; 2. Baseline Hunt-Hess grade I-III; 3. patients received endovascular treatment Exclusion Criteria: 1. Hunt-Hess grade IV-V; 2. Non-aneurysmal SAH; 3. Dementia in other diseases; 4. Lacking of 6-8 month MoCA evaluation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Antiplatelet-N group<br>Patients with ruptured aneurysm underwent coiling alone, without post-treatment antiplatelet therapy | |
| Antiplatelet-Y group<br>Patients with ruptured aneurysm underwent stent assisted coiling, with post-treatment antiplatelet therapy (aspirin and/or clopidogrel or ticagrelor) | Drug: Antiplatelet Drug<br>* aspirin and/or clopidogrel or ticagrelor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Montreal Cognitive Assessment (MoCA) Test |  | 6-8 months |
Hydrochloorthiazide and Hypernatriaemie

Study Overview
=================
Brief Summary
-----------------
Acquired hypernatremia appears to be associated with mortallity in ICU. To reduce hypernatremia and shorten the time of hypernatremia, we investigate the effect of hydrochloorthiazide compared to a placebo

Official Title
-----------------
Hypernatraemia and Diuretics in Intensive Care Patients

Conditions
-----------------
Hypernatraemia

Intervention / Treatment
-----------------
* Drug: Hydrochloorthiazide
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sodium > 142 Exclusion Criteria: no informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: hydrochloorthiazide<br>once a day 25 mg | Drug: Hydrochloorthiazide<br> <br> |
| Placebo Comparator: placebo<br>once a day placebo | Drug: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sodium level | a decrease of 5 mmol/L sodium in plama | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time hypernatraemia | decrease of duration high sodium level in plasma | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intensive care, diuretics
Incidence and Severity of Acute Respiratory Distress Syndrome (ARDS) in the French Wounded Soldiers

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the incidence of the ARDS in the French wounded soldiers.

Detailed Description
-----------------
The Acute Respiratory Distress Syndrome (ARDS) complicates war wounds. Among the repatriated wounded persons, it can appear in the first 7 days. It has been well described among American soldiers and it is known that it's serious, frequent and multifactorial. However, not a single study has described the frequency and the severity of the ARDS in French wounded soldiers. Thus the purpose of this study is to estimate the incidence and severity of the ARDS among the French wounded soldiers, admitted in continuing care and intensive care unit between 2001 and 2017. The analysis of this data collection will let us improve the medical care of the ARDS in Outside Operation.

Official Title
-----------------
Incidence and Severity of Acute Respiratory Distress Syndrome (ARDS) in the French Wounded Soldiers

Conditions
-----------------
Acute Respiratory Distress Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient evacuated from the theatre of outside operation and hospitalized in intensive care unit in France between 2001 et 2017 Exclusion Criteria: Opposition to the use of personal data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of ARDS | The appearance of ARDS is defined by a ratio of partial pressure arterial oxygen (PaO2) and fraction of inspired oxygen (FiO2) lower than 300 in 7 days after the wound. | Day 7 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess the severity of ARDS | the severity of ARDS will be assessed regarding the necessity or not of non-invasive and invasive ventilation | 7 days | 
| Description of the severity of ARDS | the therapeutic intensity will be describe with : Maximal Positive end-expiration pressure (PEEP), curarisation, nitrogen monoxide (NO), prone position , Extracorporeal membrane oxygenation. | 7 days | 
| Mortality | Assess the mortality since hospitalization | Day 90 | 
| Assessment of the severity of ARDS | the severity of ARDS will be assessed regarding duration of non-invasive and invasive ventilation | 7 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
war wounds, intensive care unit
Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This observational study is conducted in Europe. The aim of this non-interventional (observational) study is to evaluate the efficacy of liraglutide (Victoza®) and to assess the conditions of use of Victoza® in daily medical practice in France.

Official Title
-----------------
Conditions for Prescribing Liraglutide in Medical Practice and Assessment of Maintenance Level, Tolerability, and Efficacy of Victoza® (Liraglutide) in Subjects With Type 2 Diabetes

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: liraglutide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with type 2 diabetes Patients having recently started (for less than one week) or starting liraglutide (Victoza®) treatment Exclusion Criteria: Hypersensitivity (allergy) to liraglutide or to any of the excipients Patient is participating in a clinical trial at the inclusion Type 1 diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| A<br> | Drug: liraglutide<br>* Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of patients still in liraglutide treatment and having a HbA1c (glycosylated haemoglobin) value below 7.0% |  | Month 24 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in HbA1c at month 3 |  | Month 0, Month 3 | 
| Change in HbA1c at month 6 |  | Month 0, Month 6 | 
| Change in HbA1c at month 12 |  | Month 0, Month 12 | 
| Change in HbA1c at month 18 |  | Month 0, Month 18 | 
| Change in HbA1c at month 24 |  | Month 0, Month 24 | 
| Change in fasting plasma glucose (FPG) at month 3 |  | Month 0, Month 3 | 
| Change in fasting plasma glucose (FPG) at month 6 |  | Month 0, Month 6 | 
| Change in fasting plasma glucose (FPG) at month 12 |  | Month 0, Month 12 | 
| Change in fasting plasma glucose (FPG) at month 18 |  | Month 0, Month 18 | 
| Change in fasting plasma glucose (FPG) at month 24 |  | Month 0, Month 24 | 
| Change in Body Weight at Month 3 |  | Month 0, Month 3 | 
| Change in Body Weight at Month 6 |  | Month 0, Month 6 | 
| Change in Body Weight at Month 12 |  | Month 0, Month 12 | 
| Change in Body Weight at Month 18 |  | Month 0, Month 18 | 
| Change in Body Weight at Month 24 |  | Month 0, Month 24 |
Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to determine the safe use and tolerance of a peptide-based formula in children with gastrointestinal dysfunction and/or feeding intolerance.

Official Title
-----------------
Evaluation of the Safe Use and Tolerance of a Peptide-based Formula in a Pediatric Population

Conditions
-----------------
Gastrointestinal Diseases, Feeding Intolerance

Intervention / Treatment
-----------------
* Other: Peptide based enteral formula


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or nonpregnant female between 1 and 13 years of age. Subject is diagnosed with gastrointestinal dysfunction and/or feeding intolerance. Subject requires enteral tube feeding as sole source of nutrition. Exclusion Criteria: History of diabetes. Requires artificial ventilation. Requires parenteral nutrition. Subject has intestinal obstruction. Subject is receiving dialysis treatment. Subject has an allergy or intolerance to any ingredient in the study product.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 13 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Peptide Based enteral formula<br> | Other: Peptide based enteral formula<br>* Sole source nutrition as per HCP<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Stool frequency |  | 14 Days | 
| Frequency and intensity of irritability, vomiting, distension |  | 14 Days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average Energy Intake |  | 14 Days | 
| Anthropometrics |  | 14 Days | 
| Medication Use |  | 14 days |
Variation of Cerebral Blood Flow in Anterior Cerebral and Basilar Artery in Neonates and Infants in Genreal Anesthesia With Caudal Block

Study Overview
=================
Brief Summary
-----------------
With this study we want to see how the blood flow in the anterior cerebral artery (ACA) and the basilar artery (BA) after the caudal block changes.

Official Title
-----------------
Variation of Cerebral Blood Flow in Anterior Cerebral and Basilar Artery in Neonates and Infants - a Prospective Study During Planed Surgery of the Infra Umbilical Region in Combined Anaesthesia

Conditions
-----------------
Pediatric Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: opened big fontanella infraumbilical surgery Exclusion Criteria: cardiac or cerebral disease prior operation on vertebra, heart or head/brain malforamtion of head or vertebra closed fontanella contraindication for caudal block (von-Willebrand-Syndrome, haemophilia,...)

Ages Eligible for Study
-----------------
Maximum Age: 12 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| depression of blood flow in ACA & basilar artery after caudal block |  | one hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
regional anesthesia, caudal block
Comparison of the Evaluation of CAD by CT AngioScan and Coronary Angiogram

Study Overview
=================
Brief Summary
-----------------
The use of CT Coronary Angioscan (CT-AS) is gaining popularity, but its exact value as evaluation of CAD requires confirmation. We intend to compare the results of CT-AS and convention coronary angiogram results in patients who are scheduled for an ascending aorta aneurysm reparation surgery. These examens are standard of care before this surgery, so there is no additional danger or disadvantage for the patient. We hope to confirm that CT-AS is a reliable screening test for CAD in patient undergoing heart surgery for other reason than CAD.

Official Title
-----------------
Comparison of the Evaluation of CAD by CT AngioScan and Coronary Angiogram in Patient as Part of Preoperative Evaluation in Ascending Aorta Replacement Surgery Patients.

Conditions
-----------------
Coronary Artery Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ascending aorta aneurysm waiting for surgical correction Willing to participate Needing a Coronary angiogram and a CT-AS for medical reasons Exclusion Criteria: Refuse to participate Allergy to contrast material Incomplete results or having one of the test done in another hospital Arrythmia More than 6 months between the two exams

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of CAD | The CAD seen on CT-AS as compared to the results of the gold-standard test of coronary angiogram. | less than 6 monthes between two tests |
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.

Official Title
-----------------
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 1 Hepatitis C Who Relapsed After Previous Treatment

Conditions
-----------------
Chronic Hepatitis C

Intervention / Treatment
-----------------
* Drug: MP-424
* Drug: Ribavirin
* Drug: Peginterferon Alfa-2b


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Genotype 1, chronic hepatitis C Relapsers (patient who relapsed after previous treatment) Able and willing to follow contraception requirements Exclusion Criteria: Cirrhosis of the liver or hepatic failure Hepatitis B surface antigen-positive or HIV antibodies-positive History of, or concurrent hepatocellular carcinoma History of, or concurrent depression, schizophrenia; or suicide attempt in the past Pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MP-424<br> | Drug: MP-424<br>* 750 mg every 8 hours for 12 weeks<br>* Other names: Telaprevir;Drug: Ribavirin<br>* 600 - 1000 mg/day based on body weight for 24 weeks<br>Drug: Peginterferon Alfa-2b<br>* 1.5 mcg/kg/week for 24 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response) |  | After 24 weeks of follow-up |
Strategies of Self-management of Endometriosis Symptoms

Study Overview
=================
Brief Summary
-----------------
To determine the prevalence and perceived utility of self-management strategies amongst patients with endometriosis and who consult the endometriosis clinic of the Geneva University Hospital, information about these strategies will be obtained via a web-based questionnaire.

Official Title
-----------------
Strategies of Self-management of Endometriosis Symptoms: an Observational Study

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Other: online questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients consulting at the endometriosis clinic of the HUG minimum 18 years capacity to answer the questions of the questionnaire Exclusion Criteria: minor patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: online questionnaire|Web-based questionnaire about use of self-management strategies|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency of use of any self-management strategy | binary answer: yes/no of use | during the last 6 months prior to the questionnaire | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| frequency of use of the pre-specified strategies: gymnastics, rest, hypnosis, meditation, exercise, osteopathy, cold/warm, acupuncture, CBD, cannabis, alcohol, TENS, phytotherapy, curcuma, essential oils, diet | binary answer: yes/no of use | during the last 6 months prior to the questionnaire |
Easy Way of Choosing Rectangular Expander and Getting Maximum Benefit From Expanded Tissue

Study Overview
=================
Brief Summary
-----------------
Background: Tissue expanders are widely used for reconstruction of tissue defects. The choice of expander and planning the flap is complicated for the inexperienced surgeon. Objective: To demonstrate the choice of expander sizes proper for the tissue defect and maximum advancement technique during the defect coverage. Methods: The present study included 19 patients who were operated between January 2013 and January 2017. The expander projection was chosen in the manner that it would be more than the half length of the defect to be occurred and the expander width was chosen as wide as possible based on the area of its placement. After the expansion was completed, advancement method was used to cover the defect.

Official Title
-----------------
Easy Way of Choosing Rectangular Expander and Getting Maximum Benefit From Expanded Tissue

Conditions
-----------------
Burn Scar, Scalp Wound

Intervention / Treatment
-----------------
* Procedure: Skin expansion and repair with flaps


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients treated with rectangular tissue expanders. Patients who attended to at least postoperative six months control. Exclusion Criteria: Patients treated with tissue expanders other than rectangular expanders. Patients who did not attend to postoperative controls.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Skin expansion and repair with flaps<br>The tissue expander was inserted into the scalp in 17 patients and supraclavicular area in two patients. | Procedure: Skin expansion and repair with flaps<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Scar revision | Closure of defect | 6 months |